| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GENO Stock Overview
Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries.
Rewards
Risk Analysis
No risks detected for GENO from our risk checks.
Genovis AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr51.40 |
| 52 Week High | kr90.00 |
| 52 Week Low | kr40.25 |
| Beta | 1.53 |
| 1 Month Change | 7.08% |
| 3 Month Change | 1.78% |
| 1 Year Change | 1.98% |
| 3 Year Change | 110.66% |
| 5 Year Change | 1,678.55% |
| Change since IPO | -51.96% |
Recent News & Updates
If EPS Growth Is Important To You, Genovis AB (publ.) (STO:GENO) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Is There An Opportunity With Genovis AB (publ.)'s (STO:GENO) 43% Undervaluation?
How far off is Genovis AB (publ.) ( STO:GENO ) from its intrinsic value? Using the most recent financial data, we'll...
Shareholder Returns
| GENO | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -1.9% | 5.8% | 2.3% |
| 1Y | 2.0% | -52.0% | -21.8% |
Return vs Industry: GENO exceeded the Swedish Life Sciences industry which returned -52% over the past year.
Return vs Market: GENO exceeded the Swedish Market which returned -21.8% over the past year.
Price Volatility
| GENO volatility | |
|---|---|
| GENO Average Weekly Movement | 7.9% |
| Life Sciences Industry Average Movement | 7.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in SE Market | 12.6% |
| 10% least volatile stocks in SE Market | 4.5% |
Stable Share Price: GENO is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: GENO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 36 | Fredrik Olsson | https://www.genovis.com |
Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries. The company offers FabALACTICA, a cysteine protease that digests human IgG1; FabRICATOR, an enzyme that primarily digests the hinge region of IgG; and FabRICATOR Z, an enzyme for the digestion of mouse IgG2a and IgG3, as well as for generating a homogenous pool of F(ab')2 and Fc fragments. It also provides FabULOUS (SpeB), an enzyme for the digestion of IgG in the hinge region; and GingisKHAN, a cysteine protease that digests human IgG1 at a specific site above the hinge.
Genovis AB (publ.) Fundamentals Summary
| GENO fundamental statistics | |
|---|---|
| Market Cap | kr3.39b |
| Earnings (TTM) | kr36.05m |
| Revenue (TTM) | kr116.70m |
93.3x
P/E Ratio28.8x
P/S RatioIs GENO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENO income statement (TTM) | |
|---|---|
| Revenue | kr116.70m |
| Cost of Revenue | kr14.31m |
| Gross Profit | kr102.39m |
| Other Expenses | kr66.34m |
| Earnings | kr36.05m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 15, 2022
| Earnings per share (EPS) | 0.55 |
| Gross Margin | 87.74% |
| Net Profit Margin | 30.89% |
| Debt/Equity Ratio | 0.0% |
How did GENO perform over the long term?
See historical performance and comparison